AbbVie Reports First-Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall St muted as markets monitor Hormuz situation; data awaited
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil rises 4% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Abbvie (ABBV) PT Lowered to $187 at Barclays
April 29, 2024 5:22 AM EDTBarclays analyst Carter Gould lowered the price target on Abbvie (NYSE: ABBV) to $187.00 (from $195.00) while maintaining a Overweight rating.
The analyst comments "Humira erosion and transient headwinds drive reframing of '25 EPS growth, though LT profile keeps us positively biased; lowering PT to $187."
... More